#NewProfilePic

#sarcoma team at the SBOC Annual Meeting in Rio de Janeiro! Great discussions involving adjuvant therapy for GIST and multidisciplinary management of extremity soft tissue sarcoma.

Don't miss our poster No 245 on #neoadjuvant #radiotherapy and #immunotherapy with pembrolizumab and soluble LAG-3 protein eftilagimod in resectrable soft tissue #sarcoma 🔸preliminary data of 21/40pts 🔸encouraging path responses ⁉️ for more join us at poster reception #CTOS2024

Clinical Cancer Research #Desmoid re-enforcing a message here aacrjournals.org/clincancerres/…

Sharing our new case report einstein (São Paulo) of a challenging case of pseudomyogenic hemangioendothelioma, an ultra-rare sarcoma with <1,000 cases reported. Sequential systemic treatment with everolimus & pazopanib (with response!) offers insights into this tumor’s natural

🚨🥁🥁🥁By popular demand, I’m pleased to share the top Precision Oncology papers of 2024! 📚✨ #HappyNewYear2025 👉Please feel free to add your favorite papers to the X thread. Let’s celebrate the advancements in our field together & looking forward for ground breaking advances

What an amazing game by this special player. Fonseca is the hero we need! 🇧🇷

Rare cancers deserve a louder voice in research. On this #WorldCancerDay, we’re shining a light on the power of rare cancer communities who can and do help drive discoveries. 💜 Learn more at hubs.ly/Q0356-sw0. #Sarcoma #RareCancer #PediCancer #TRCC

📍Another tumor agnostic drug 👉🏼 #PrecisionMedicine for the 🏆👉🏼Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | New England Journal of Medicine NEJM nejm.org/doi/full/10.10…

Great publication on soft tissue #sarcoma in Latin America Most frequently reported sarcoma types were liposarcoma (24%) and synovial sarcoma (16%). Most tumors were high-grade (68%). Tumor sizes varied widely, with a mean size of 10 cm. Only 46% R0 resection.

Thank you to Clinical Cancer Research Agenus Cancer League Colo CU Cancer Center for support in this investigator initiated study, doxorubicin plus dual checkpoint inhibitors for advanced sarcomas!

Sharlene Gill, MD, MPH, MBA, FASCO ASCO Alliance for Clinical Trials in Oncology Let’s keep in mind that ATOMIC is ph 3 trial whereas neoadjuvant data, while very provocative, are non randomized with limited patient numbers and short follow-up. Agree that contribution of chemotherapy cannot be discerned but cannot exclude contribution.

Sensational talk given by Mark Lewis, MD, FASCO at ASCO plenary today!!!! 🕊️🦅

Great presentation by Mark Lewis, MD, FASCO With the help of AI, an additional definition of surrogate endpoint: “It’s the GPS pin your doctor drops on your health journey, insisting you detour toward it—only for you to arrive and wonder why the scenery looks exactly the same” #ASCO25